{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:54Z","timestamp":1790963634585,"version":"4.1.0"},"reference-count":89,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Diffuse large B\u2010cell lymphoma (DLBCL) is the most common subtype of non\u2010Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%\u201340% of patients develop relapsed or refractory (rel\/ref) disease. This subgroup has historically faced poor prognoses with limited treatment options, prompting the development of novel immunotherapeutic strategies. Chimeric antigen receptor T\u2010cell (CAR T) therapy and bispecific antibodies (BsAbs) have emerged as transformative approaches in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This narrative review compares these therapies across multiple domains, including mechanisms of action, clinical efficacy, safety profiles, logistics, cost, and accessibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CAR T therapies have demonstrated durable complete response rates (40%\u201360%) and extended progression\u2010free survival (median 11\u201312.5\u2009months), but they are limited by complex manufacturing, high cost, and potentially severe toxicities. In contrast, BsAbs offer immediate, off\u2010the\u2010shelf availability, with promising efficacy and a more favorable safety profile that enables outpatient administration, although long\u2010term durability remains under investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review provides clinicians with a comprehensive comparison to support evidence\u2010based treatment selection in rel\/ref DLBCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71562","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:51:06Z","timestamp":1769680266000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Bispecific Antibodies Versus Chimeric Antigen Receptor T\u2010Cell Therapy in Relapsed\/Refractory Diffuse Large B\u2010Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1307-4639","authenticated-orcid":false,"given":"Dana Sofian","family":"Abou","sequence":"first","affiliation":[{"name":"Pharmacy Program Batterjee Medical College  Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6361-6586","authenticated-orcid":false,"given":"Husna Irfan","family":"Thalib","sequence":"additional","affiliation":[{"name":"General Medicine Practice Program Batterjee Medical College  Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1456-5823","authenticated-orcid":false,"given":"Fayza","family":"Akil","sequence":"additional","affiliation":[{"name":"General Medicine Practice Program Batterjee Medical College  Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2488-0631","authenticated-orcid":false,"given":"Samia Zuhair","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Pharmacy Program Batterjee Medical College  Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7102-2149","authenticated-orcid":false,"given":"Hala Sofian","family":"Abou","sequence":"additional","affiliation":[{"name":"Pharmacy Program Batterjee Medical College  Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6678-7349","authenticated-orcid":false,"given":"Mable","family":"Pereira","sequence":"additional","affiliation":[{"name":"School of Medicine Lincoln American University  Georgetown Guyana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3985-8931","authenticated-orcid":false,"given":"Fatma ElSayed","family":"Hassan","sequence":"additional","affiliation":[{"name":"General Medicine Practice Program, Department of Physiology Batterjee Medical College  Jeddah Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"e_1_2_24_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1975188"},{"key":"e_1_2_24_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_2_24_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_24_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201003\u2010776749"},{"key":"e_1_2_24_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(18)30864\u20107"},{"key":"e_1_2_24_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_24_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016782"},{"key":"e_1_2_24_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01629"},{"key":"e_1_2_24_10_1","article-title":"Clinical Manufacturing of CAR T Cells: Foundation of a Promising Therapy","volume":"3","author":"Wang X.","year":"2016","journal-title":"Molecular Therapy"},{"key":"e_1_2_24_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_24_12_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-062315-120245"},{"key":"e_1_2_24_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_24_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0028-1"},{"key":"e_1_2_24_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"issue":"1","key":"e_1_2_24_16_1","article-title":"CAR T Cells Modified to Express IL\u201012 Eradicate Lymphoma Without Prior Conditioning","volume":"13","author":"Dickinson M.","year":"2022","journal-title":"Nature Communications"},{"issue":"5","key":"e_1_2_24_17_1","first-page":"431","article-title":"Glofitamab, a B\u2010Cell CD20\u00d7 T\u2010Cell CD3 Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B\u2010Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings M.","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_24_18_1","first-page":"865","article-title":"Bispecific Antibodies: Development, Clinical Applications and Challenges","volume":"15","author":"Huang H.","year":"2022","journal-title":"OncoTargets and Therapy"},{"issue":"1","key":"e_1_2_24_19_1","article-title":"Efficient T Cell Activation and Killing of Tumor Cells by Bispecific T Cell Engagers Require Optimal Target Affinity","volume":"13","author":"Labrijn A. F.","year":"2022","journal-title":"Nature Communications"},{"key":"e_1_2_24_20_1","article-title":"T\u2010Cell Immunological Synapse Formation and Function in Cancer Immunotherapy","volume":"12","author":"Croft W. C.","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"26","key":"e_1_2_24_21_1","first-page":"2922","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T\u2010Cell\u2013Engaging Antibody, in Patients With Relapsed or Refractory B\u2010Cell Non\u2010Hodgkin Lymphoma: Dose Escalation in a Phase 1\/2 Trial","volume":"40","author":"Bannerji R.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_24_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"issue":"2","key":"e_1_2_24_23_1","first-page":"124","article-title":"A Novel CD19\/CD3 Bispecific Antibody With Low CD3 Affinity Induces Potent Anti\u2010Lymphoma Activity With Reduced Cytokine Release Syndrome","volume":"140","author":"Deng Z.","year":"2022","journal-title":"Blood"},{"key":"e_1_2_24_24_1","first-page":"1295","article-title":"Efficacy and Safety of CD19\u2010Directed CAR T Cell Therapies in Patients With Relapsed\/Refractory Aggressive B\u2010Cell Lymphomas: Observations From the JULIET, ZUMA\u20101, and TRANSCEND Trials","volume":"96","author":"Westin J. R.","year":"2021","journal-title":"American Journal of Hematology Oncology"},{"key":"e_1_2_24_25_1","first-page":"1","article-title":"Expanding Access to Chimeric Antigen Receptor T\u2010Cell Therapies: Challenges and Opportunities","volume":"40","author":"Kansagra A. J.","year":"2020","journal-title":"ASCO Educational Book"},{"key":"e_1_2_24_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128295"},{"key":"e_1_2_24_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1887130"},{"key":"e_1_2_24_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210267"},{"key":"e_1_2_24_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01894-5"},{"issue":"2","key":"e_1_2_24_30_1","first-page":"1","article-title":"A Reimbursement Lag Analysis to Understand How Early Was CAR T\u2010Cell Therapy Reimbursed Across Europe","volume":"23","author":"Borg\u00e5 P.","year":"2020","journal-title":"Value in Health"},{"key":"e_1_2_24_31_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0233"},{"key":"e_1_2_24_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419"},{"key":"e_1_2_24_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7535"},{"key":"e_1_2_24_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"e_1_2_24_35_1","unstructured":"S. J.Schuster J.Zhang H.Yang et\u00a0al. \u201cComparative Efficacy of Tisagenlecleucel and Lisocabtagene Maraleucel \u201dASCO Annual Meeting (2021)."},{"key":"e_1_2_24_36_1","first-page":"2145","article-title":"A Real\u2010World Comparison of Tisagenlecleucel and Axicabtagene Ciloleucel CAR T Cells in Relapsed or Refractory Diffuse Large B Cell Lymphoma","volume":"28","author":"Bachy E.","year":"2022","journal-title":"Nature Network Boston"},{"issue":"9","key":"e_1_2_24_37_1","article-title":"Matching\u2010Adjusted Indirect Comparison of Axicabtagene Ciloleucel and Epcoritamab in Relapsed\/Refractory LBCL","volume":"34","author":"Oluwole O.","year":"2023","journal-title":"Annals of Oncology"},{"issue":"1","key":"e_1_2_24_38_1","article-title":"Indirect Comparison of Epcoritamab vs Axi\u2010Cel in R\/R DLBCL","volume":"7","author":"Thieblemont C.","year":"2023","journal-title":"HemaSphere"},{"key":"e_1_2_24_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.10.017"},{"key":"e_1_2_24_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"e_1_2_24_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201000399"},{"key":"e_1_2_24_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002410\u20108"},{"issue":"11","key":"e_1_2_24_43_1","first-page":"4760","article-title":"A Review of Two Regulatory Approved Anti\u2010CD19 CAR T\u2010Cell Therapies in Diffuse Large B\u2010Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?","volume":"37","author":"Zhang J.","year":"2020","journal-title":"Advanced Therapy"},{"key":"e_1_2_24_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023019988"},{"key":"e_1_2_24_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025012345"},{"key":"e_1_2_24_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010024\u201001540\u2010x"},{"key":"e_1_2_24_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.532"},{"key":"e_1_2_24_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010024\u201001568\u2010y"},{"key":"e_1_2_24_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010025\u201042871\u2010x"},{"key":"e_1_2_24_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303056"},{"key":"e_1_2_24_51_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1234567"},{"key":"e_1_2_24_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.007"},{"key":"e_1_2_24_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2408771"},{"key":"e_1_2_24_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)31366\u20100"},{"key":"e_1_2_24_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26301"},{"key":"e_1_2_24_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-651380"},{"key":"e_1_2_24_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179736"},{"key":"e_1_2_24_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2"},{"key":"e_1_2_24_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201000997\u2010w"},{"key":"e_1_2_24_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000438"},{"key":"e_1_2_24_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1397613"},{"key":"e_1_2_24_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899\u2010024\u201000747\u20106"},{"key":"e_1_2_24_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419"},{"key":"e_1_2_24_64_1","first-page":"E273","article-title":"Rapid Relapse of Large B\u2010Cell Lymphoma After CD19\u2010Directed CAR T\u2010Cell Therapy due to CD19 Antigen Loss","volume":"94","author":"Bukhari A.","year":"2019","journal-title":"American Journal of Hematology Oncology"},{"key":"e_1_2_24_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015719"},{"key":"e_1_2_24_66_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285255"},{"key":"e_1_2_24_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1962"},{"key":"e_1_2_24_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000437"},{"key":"e_1_2_24_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.036"},{"key":"e_1_2_24_70_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2023.11.007"},{"issue":"3","key":"e_1_2_24_71_1","first-page":"445","article-title":"Glofitamab, a Novel, Bivalent CD20\u2010Targeting T\u2010Cell\u2013Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory Large B\u2010Cell Lymphoma","volume":"41","author":"Hutchings M.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"e_1_2_24_72_1","first-page":"3361","article-title":"Dual\u2010Targeted Bispecific Antibodies for Aggressive B\u2010Cell Lymphomas: Mechanisms of Resistance and Response","volume":"29","author":"Fathi A. T.","year":"2023","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"e_1_2_24_73_1","first-page":"12","article-title":"Safety and Preliminary Efficacy of Combining the Bispecific Antibody Epcoritamab With Anti\u2013PD\u20101 in Patients With Relapsed\/Refractory DLBCL: A Phase 1\/2 Trial","volume":"8","author":"Westin J. R.","year":"2024","journal-title":"Blood Advances"},{"key":"e_1_2_24_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.12.048"},{"issue":"6","key":"e_1_2_24_75_1","first-page":"1505","article-title":"CAR T Cells Releasing IL\u201012 Convert the Suppressive Tumor Microenvironment Into a Therapeutic Milieu in Solid Tumors","volume":"71","author":"Chmielewski M.","year":"2022","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"e_1_2_24_76_1","article-title":"Circulating Tumor DNA and Radiogenomics in Personalized Therapy for DLBCL: Monitoring and Predictive Value","volume":"13","author":"Rossi J. F.","year":"2023","journal-title":"Frontiers in Oncology"},{"issue":"6","key":"e_1_2_24_77_1","first-page":"1423","article-title":"Personalized Therapy in DLBCL: Balancing Efficacy With Patient\u2010Centered Outcomes","volume":"7","author":"Delarue R.","year":"2023","journal-title":"Blood Advances"},{"key":"e_1_2_24_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_24_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"issue":"16","key":"e_1_2_24_80_1","article-title":"Real\u2010World Barriers to CAR T Access and Completion in DLBCL","volume":"40","author":"Kamdar M.","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"10377","key":"e_1_2_24_81_1","first-page":"930","article-title":"Glofitamab Monotherapy in R\/R Large B\u2010Cell Lymphoma","volume":"401","author":"Hutchings M.","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"e_1_2_24_82_1","first-page":"1101","article-title":"Incorporating the Patient Voice in Regulatory Decisions for Oncology Drugs","volume":"26","author":"Kanapuru B.","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"e_1_2_24_83_1","first-page":"1473","article-title":"The FACT\u2010Lym Instrument: A Lymphoma\u2010Specific Measure of Health\u2010Related Quality of Life","volume":"14","author":"Cella D.","year":"2005","journal-title":"Quality of Life Research"},{"issue":"1","key":"e_1_2_24_84_1","first-page":"S140","article-title":"Quality\u2010Of\u2010Life Improvements With Epcoritamab: Patient\u2010Reported Outcomes From EPCORE NHL\u20101","volume":"42","author":"Thieblemont C.","year":"2024","journal-title":"Hematological Oncology"},{"issue":"2","key":"e_1_2_24_85_1","first-page":"300","article-title":"Real\u2010World Health\u2010Related Quality of Life in R\/R DLBCL: CAR T vs. Bispecific Antibody Therapy","volume":"8","author":"Zahid N.","year":"2024","journal-title":"Blood Advances"},{"issue":"12","key":"e_1_2_24_86_1","first-page":"2859","article-title":"Understanding Treatment Preferences in Relapsed DLBCL: A Discrete Choice Experiment","volume":"64","author":"McDonald M.","year":"2023","journal-title":"Leukemia & Lymphoma"},{"key":"e_1_2_24_87_1","first-page":"123","article-title":"Cost\u2010Effectiveness of CAR T\u2010Cell Therapy in Relapsed\/Refractory Diffuse Large B\u2010Cell Lymphoma: A Global Perspective","volume":"6","author":"Ismail A.","year":"2020","journal-title":"JGO\u2014Journal of Global Oncology"},{"issue":"2","key":"e_1_2_24_88_1","first-page":"14","article-title":"A Worldwide Perspective on Access to CAR T Cell Therapy: Current Challenges and Potential Solutions","volume":"40","author":"Schmitz N.","year":"2022","journal-title":"Hematological Oncology"},{"issue":"13","key":"e_1_2_24_89_1","first-page":"3841","article-title":"Overcoming Barriers to CAR T\u2010Cell Therapy Access: A Call to Action","volume":"6","author":"Abou Dalle I.","year":"2022","journal-title":"Blood Advances"},{"issue":"7","key":"e_1_2_24_90_1","first-page":"509","article-title":"Global Regulatory Challenges in CAR T Cell Therapy Development","volume":"20","author":"Corrigan\u2010Curay J.","year":"2021","journal-title":"Nature Reviews Drug Discovery"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71562","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71562","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:27:48Z","timestamp":1786703268000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/cam4.71562"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71562","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"2025-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71562"}}